S Gerdes, R Ostendorf, A Süß, T Schadeck, F Taut, J Makuc, L Scharfenberger, S Jacobsen, N Trenkler, J Behrens, G Joks, S Tabori, D Mortazawi
BACKGROUND: G-EPOSS is a prospective, non-interventional, German multicentre study of patients with moderate-to-severe plaque psoriasis receiving guselkumab, a therapeutic monoclonal antibody targeting interleukin-23, in a real-world setting. OBJECTIVES: The objective of the study was to evaluate the effectiveness and safety of guselkumab, including its impact on skin, health-related quality of life (HRQoL), sexuality, and perceived stigmatization. METHODS: Patients (≥18 years old) received guselkumab per routine clinical practice...
April 11, 2024: Journal of the European Academy of Dermatology and Venereology: JEADV